Chordate Medical reports Q3 and carries out rights issue – Biostock interviews Anders Weilandt

Chordate’s CEO Anders Weilandt is interviewed by the news service Biostock about the newly released interim report for July-September 2022 and the planned rights issue. Anders Weilandt on the quarter:

” As the most exciting quarter so far in the company’s history – is probably the short answer. First getting the results of the subgroup, and then the analysis of the entire study material, is a confirmation of so many years of hard work and beats most of what the company has experienced. The entire Chordate project has now been “de-risked” down to a completely new and much more comfortable level.”

Read the full interview here.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy